Finxora Logo
Sign In
Pharma Project Performance: Reading the Numbers for ROI
Back to Blog

Pharma Project Performance: Reading the Numbers for ROI

FINXORA
6 min read
pharmaceuticals
project management
finance
ROI
investment analysis

Pharma projects tie up capital in plant, validation and inventory. Here are the numbers to track on a pharma project report and after commissioning.

Why a pharma project reads differently

A pharmaceutical unit funded by a bank loan has an unusual shape. Money leaves early and in bulk for land, building, plant, utilities and quality systems, while revenue arrives later and in a thinner stream, because batches must be validated and approvals obtained before commercial supply begins. Then, once the unit is running, a large part of the money sits in inventory: raw material, packing material, work in progress and finished goods waiting for release. Reading the performance of a pharma project therefore means watching the investment, the operating cycle and the debt service together, not one after another.

The three layers to track

The investment

What the project cost, how it was funded, and what it earns on the money invested. Promoters and equity investors often look at return on investment, return on capital employed, and at discounted measures such as net present value and internal rate of return for the project as a whole. Those discounted measures belong to the promoters' own appraisal; the bank's appraisal rests on the same statements but reads debt service and security first.

The operation

Once production starts, the working of the unit shows up in a handful of figures: capacity utilisation, gross margin, contribution, inventory days, receivable days and the cash conversion cycle. In pharma these move for reasons that have little to do with sales effort. A long validation batch, a change in the approved pack size or a delay in institutional payment can shift inventory and receivables by weeks without any change in orders.

The debt service

Every rupee of term loan has to be repaid from cash the unit generates. DSCR, computed for each year, is the summary figure: net profit plus depreciation plus term-loan interest, divided by principal plus interest. Alongside it sit the interest coverage ratio and the break-even point, which show how much room exists before either the repayment or the margin comes under strain.

The figures worth watching

  • Capacity utilisation - the gap between installed and used capacity tells you whether the projected sales rest on demand or on optimism.
  • Gross margin and contribution - material and conversion cost per batch against the realised rate; a falling contribution ratio pushes break-even up quickly.
  • Inventory days - raw material, packing, work in progress and finished goods separately. A single combined figure hides which stage is holding the money.
  • Receivable days - institutional and export buyers can take longer than trade customers, and the ageing needs to be watched against the credit terms offered.
  • Cash conversion cycle - inventory plus receivable days minus payable days, which is the length of time the business funds before collection.
  • DSCR by year - with the average across the repayment period, and a note on any year where cover falls below one.
  • Break-even and margin of safety - the sales value at which fixed costs are covered, and how far projected sales sit above it.
  • Return on capital employed - operating profit against the capital employed, which shows whether the investment is earning more than it costs.

Where pharma project reports usually go wrong

  • Sales assumed from the first month, with no allowance for validation batches, stability studies or the approval timeline.
  • Inventory understated, so the working capital limit proposed is smaller than the cycle actually needs.
  • Receivables from institutional buyers projected on the same terms as trade sales, which understates the funding gap.
  • Power, effluent treatment and quality-control costs treated as minor when they are a material fixed cost in a formulation unit.
  • Break-even left close to projected sales, so a quarter's delay in approvals pushes the unit below the line.
  • Interest and depreciation in the projections that do not match the loan terms and the asset schedule.
  • A capacity utilisation ramp that improves every year with no stated reason, such as an added product line or a supply contract.

Funding a pharma project

The capital side is usually a mix: promoter contribution, a term loan for building, plant, utilities and quality systems, and a working capital limit for the operating cycle. Capital subsidy and interest subvention are available under some state and central schemes, and where a subsidy is expected, the project report should state whether it is a flat amount or a percentage of the loan, and whether it is released upfront or after commissioning, because the treatment changes the repayment schedule.

The working capital limit is assessed on CMA data: the current assets and current liabilities statement with holding levels, the maximum permissible bank finance, and the ratio set. For a pharma borrower, the stock and debtor days in that working are the figures that decide whether the limit is adequate.

Keeping the report and the actuals comparable

A project report is only useful for performance review if the statements in it are built the way the unit's accounts will be built. That means the profit and loss account, balance sheet and cash flow drawn from one set of linked figures, with depreciation fixed to the asset schedule and interest to the loan terms. When the audited results arrive, the variance can then be read line against line: sales against projection, material cost as a percentage of sales, inventory days, DSCR, and the break-even point recalculated on the actual cost structure.

Building the workings in one place

Finxora's project report software builds the project cost, means of finance, projected profit and loss account, balance sheet, cash flow, depreciation chart, EMI schedules and DSCR from one set of inputs, and adds ratio analysis, break-even with the margin of safety, and the turnover method and MPBF working. Multiple term loans, a moratorium, a subsidy entered as an amount or a percentage and interest subvention are supported, and revenue and expense rows can follow the months the unit actually operates rather than a flat monthly spread.

The same figures can be carried into CMA data when the working capital limit is appraised, so the stock and debtor holding levels agree with the project report. A filled sample report shows the section order and the ratio and break-even pages as they print. The project report software page lists everything the report contains.

A review checklist for a running unit

  1. Compare actual capacity utilisation with the projection before reading any profit figure.
  2. Split inventory into its stages and review each one's days.
  3. Review receivable ageing against the credit terms offered to institutional buyers.
  4. Recompute DSCR on actual figures and compare it with the projected average.
  5. Recalculate break-even on the current cost structure and check the margin of safety.
  6. Compare return on capital employed with the cost of the borrowing.

Frequently Asked Questions

Published on February 14, 2026

Updated on August 28, 2026

Back to Blog

Need bank-ready financials? Create a CMA report or a project report with Finxora in minutes.